{"nctId":"NCT00289211","briefTitle":"C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks","startDateStruct":{"date":"2005-03-14","type":"ACTUAL"},"conditions":["Hereditary Angioedema"],"count":83,"armGroups":[{"label":"C1INH-nf","type":"EXPERIMENTAL","interventionNames":["Biological: C1 esterase inhibitor [human] (C1INH-nf)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (saline)"]}],"interventions":[{"name":"C1 esterase inhibitor [human] (C1INH-nf)","otherNames":[]},{"name":"Placebo (saline)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented HAE\n* Normal C1q level\n\nExclusion Criteria:\n\n* Low C1q level\n* B-cell malignancy\n* Presence of anti-C1INH autoantibody\n* History of allergic reaction to C1INH or other blood products\n* Narcotic addiction\n* Current participation in any other investigational drug study or within the past 30 days\n* Participation in a C1 esterase inhibitor trial, or received blood or a blood product in the past 90 days\n* Pregnancy or lactation\n* Any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Beginning of Substantial Relief of the Defining Symptom","description":"Randomized subjects assessed their symptoms every 15 minutes up to 4 hours after the initial dose of blinded study drug or until substantial relief of the defining symptom was achieved. Substantial relief was defined as 3 consecutive assessments of improvement of the defining symptom. Beginning of substantial relief was considered the first of the 3 consecutive assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Beginning of Substantial Relief of the Defining Symptom","description":"Randomized subjects assessed their symptoms every 15 minutes up to 4 hours after the initial dose of blinded study drug or until substantial relief of the defining symptom was achieved. Substantial relief was defined as 3 consecutive assessments of improvement of the defining symptom. Beginning of substantial relief was considered the first of the 3 consecutive assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Complete Resolution of the HAE Attack","description":"Randomized subjects were contacted 72-96 hours (3-4 days) after discharge from the study site to determine when complete resolution of the HAE attack occurred.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"31.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Antigenic C1 Inhibitor (C1INH) Serum Levels","description":"Change in antigenic C1INH serum levels from pre-infusion to 1-, 2-, 4-, and 12 hours after the initial dose of blinded study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"22.21"},{"groupId":"OG001","value":"13.0","spread":"16.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"8.86"},{"groupId":"OG001","value":"-0.9","spread":"9.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"12.86"},{"groupId":"OG001","value":"0.5","spread":"6.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"8.92"},{"groupId":"OG001","value":"0.4","spread":"6.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"11.21"},{"groupId":"OG001","value":"-0.8","spread":"4.39"}]}]}]},{"type":"SECONDARY","title":"Functional C1INH Serum Levels","description":"Percent change in functional C1INH serum levels from pre-infusion to 1-, 2-, 4-, and 12 hours after the initial dose of blinded study drug. Functional C1INH serum levels are expressed as a percent of total detectable C1INH (ie, functional C1INH/total detectable C1INH).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":"22.62"},{"groupId":"OG001","value":"33.7","spread":"29.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":"23.94"},{"groupId":"OG001","value":"-6.4","spread":"23.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":"23.70"},{"groupId":"OG001","value":"1.0","spread":"12.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":"28.22"},{"groupId":"OG001","value":"4.3","spread":"26.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":"17.24"},{"groupId":"OG001","value":"5.1","spread":"32.09"}]}]}]},{"type":"SECONDARY","title":"Complement C4 Serum Levels","description":"Change in complement C4 serum levels from pre-infusion to 1-, 2-, 4-, and 12 hours after the initial dose of blinded study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"7.79"},{"groupId":"OG001","value":"6.7","spread":"5.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"5.59"},{"groupId":"OG001","value":"-0.9","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"8.12"},{"groupId":"OG001","value":"-1.1","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"5.62"},{"groupId":"OG001","value":"-0.5","spread":"1.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"6.33"},{"groupId":"OG001","value":"0.1","spread":"2.07"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Dermatitis contact","Injection site rash","Tetany"]}}}